Benefits of global partnerships to facilitate access to medicines in developing countries: A multi-country analysis of patients and patient outcomes in GIPAP

Globalization and Health

Volumn 5, Issue , 2009, Pages

  Kanavos, Panos ^a   Vandoros, Sotiris ^a   Garcia Gonzalez, Pat ^b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b Max Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE CLASS; BLOOD; CANCER; DEVELOPING WORLD; DISEASE TREATMENT; HEALTH CARE; MEDICINE; NONGOVERNMENTAL ORGANIZATION; OCCUPATION; PARTNERSHIP APPROACH; PUBLIC ACCESS; PUBLIC HEALTH; REGRESSION ANALYSIS; SOCIOECONOMIC CONDITIONS; SURVIVAL;

ADULT; ARTICLE; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; DEMOGRAPHY; DEVELOPING COUNTRY; FEMALE; HEALTH CARE ACCESS; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICINE; OCCUPATION; PRIORITY JOURNAL; SOCIOECONOMICS;

EID: 79960141638     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-5-19     Document Type: Article

References (26)

1. Mrazek MF, Fidler A. Access to pharmaceuticals and regulation in the Commonwealth of Independent States. Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality 2004, 334-345. Open University Press: Buckingham, Mossialos E, Mrazek M, Walley T.
2. Hovhannisyan SG, Tragakes E, Lessof S, Aslanian H, Mkrtchyan A. Health Care Systems in Transition: Armenia 2001, Copenhagen: European Observatory on Health Care Systems.
3. World Bank Improving Transparency in Pharmaceutical Systems: Strengthening Critical Decision Points Against Corruption 2002, Washington, DC: World Bank, World Bank.
4. Dalziel K, Round A, Stein K, Garside R, Price A. "Effectiveness and cost-effectiveness of imatinib for the first-line treatment of chronic myeloid leukemia in chronic phase: a systematic review and economic analysis". Health Technology Assessment 2004, 8(28):1-120.
5. Reed SD, Anstrom LJ, Lubmer MS, Glendenning GA, Schulman MD. "Cost-effectiveness of imatinib versus interferon-α plus low-does cytarabine for patients with newly diagnosed chronic -phase chronic myeloid leukemia". Cancer 101:2574-2583. 10.1002/cncr.20694, 15493042.
6. Dalziel K, Round A, Stein K, Garside R, Price A. "Cost-effectiveness of imatinib compared with Interferon-α or Hydroxycarbamide for first-line treatment of Chronic Myeloid Leukemia". Pharmacoeconomics 2005, 23(5):515-526. 10.2165/00019053-200523050-00010, 15896102.
7. The Max Foundation 2008, accessed August 2008, The Max Foundation., http://www.themaxfoundation.org
8. Ngoasong MZ. The emergence of health partnerships as facilitators of access to medication in Africa: A narrative policy analysis. Soc Sci Med 2009, 68:949-956. 10.1016/j.socscimed.2008.12.027, 19152991.
9. Kanavos P, Holmes P. Bring on the light: The coming defeat of blinding trachoma. Financial flows to Global Partnerships 2004, Report for the Department for International Development, London, 17 February.
10. International Trachoma Initiative (ITI) International Trachoma Initiative - 10th Anniversary Report 2008, International Trachoma Initiative (ITI).
11. Burnham G, Mebrahtu T. the Delivery of Invermecin (Mectizan). Tropical Medicine and International Health 2008, 9(4):A26-A44., http://www.who.int/hiv/AAI_fs_4Q2005.pdf
12. Accelerating Access Initiative (AAI, 2006) AAI - Fact Sheet. accessed 20 April 2009, Accelerating Access Initiative (AAI, 2006).
13. Lassarat S, Jootar S. Ongoing challenges of a global international patient assistance program. Annals of Oncology 2006, 17(Supplement 8):43-46. 10.1093/annonc/mdl987, 16249214.
14. Verbeek M. A Guide to Modern Econometrics 2004, John Wiley & Sons, London, 2.
15. Greene WH. Surveillance Epidemiology and End Results. Econometric Analysis 2002, Prentice Hall, New Jersey, Fifth.
16. National Cancer Institute 2006, National Cancer Institute., http://seer.cancer.gov/data/
17. Medstore International 2009, accessed 8 June 2009, Medstore International., http://www.medstoreinternational.com/buy-Gleevec.php
18. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM. "Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon- treatment". Blood 2008, 111(3):1039-1043. 10.1182/blood-2007-07-103523, 17932248.
19. Darkow T, Henk HJ, Thomas SK, Feng W, Baldali J-F, Goldberg GA, Hatfield A, Cortes J. Treatment interruptions and non-adherence with imatinib and associated health care costs: a retrospective analysis among managed care patients with CML. Pharmacoeconomics 2007, 25(6):481-96. 10.2165/00019053-200725060-00004, 17523753.
20. Sari N, Langenbrunner JC. Consumer out-of-pocket spending for pharmaceuticals in Kazakhstan: implications for sectoral reform. Health Policy and Planning 2001, 16(4):428-34. 10.1093/heapol/16.4.428, 11739368.
21. World Bank 'Assessing Aid: What Works, What Doesn't and Why'. 2003, World Bank Washington, DC, World Bank., http://web.worldbank.org/WBSITE/EXTERNAL/EXTDEC/EXTRESEARCH/EXTPRRS/0,,contentMDK:22307401~pagePK:478097~piPK:477636~theSitePK:477633~isCURL:Y,00.html
22. World Health Organisation Guidelines for Drug Donations 1999, The World Health Organization, the WHO Department of Essential Drugs and Other Medicines, Geneva, World Health Organisation.
23. World Health Organisation Operational Guidelines for Good Pharmaceutical Procurement 1999, The World Health Organization, the WHO Department of Essential Drugs and Other Medicines, Geneva, World Health Organisation.
24. World Bank Uzbekistan Living Standards Assessment: Health, Nutrition and Population 2002, Washington, DC: World Bank, World Bank.
25. Karnitski G. Health Care Systems in Transition: Belarus 1997, Copenhagen: European Observatory on Health Care Systems.
26. Tchernjavski V. Health Care Systems in Transition: Russian Federation 1998, Copenhagen: European Observatory on Health Care Systems.